Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation
Abstract ERBB2 mutations are found in about 2% of patients with non‐small cell lung cancer (NSCLC). A recent study reported that pyrotinib (an irreversible pan ErbB inhibitor) had superior antitumor effect compared to other tyrosine kinase inhibitor therapies in patients with ERBB2 mutations. Bone m...
| Glavni autori: | , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Wiley
2020-07-01
|
| Serija: | Thoracic Cancer |
| Teme: | |
| Online pristup: | https://doi.org/10.1111/1759-7714.13480 |